A ntiplatelet therapy is the cornerstone of treatment for patients with acute myocardial infarction (MI), particularly for patients who undergo percutaneous coronary intervention (PCI); however, ≤40% of patients treated with adenosine diphosphate receptor inhibitor (ADPri) therapy have high on-treatment platelet reactivity (HPR), suggesting an inadequate platelet inhibition response that has been associated with increased risk of cardiovascular adverse events, including stent thrombosis. [1] [2] [3] [4] The rate of HPR is lower with the use of higher potency ADPri.
TRANSLATE-POPS Study
function tests can rapidly and reproducibly assess the degree of response to treatment; therefore, these tests can assist clinicians in identifying patients at increased risk of cardiovascular events who may potentially benefit from adjustments in antiplatelet therapy. Yet to date, randomized studies assessing strategies of systematic platelet function testing for the purpose of treatment adjustment have not demonstrated improvements in clinical outcomes among patients with HPR. [6] [7] [8] These studies used varying threshold definitions for HPR, had strict protocol-driven treatment adjustment strategies, included mostly low-risk patients, and were generally underpowered to examine clinical outcomes. 4 The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (ACS)-Prospective, Open Label, Antiplatelet Therapy Study (TRANSLATE-POPS) used a cluster-randomized design, built into an ongoing observational study (TRANSLATE-ACS study), to assess the real-world impact of platelet function testing in a setting in which clinicians are able to respond to test results without protocol-mandated treatment strategies. We hypothesized that (1) providing clinicians with routine no-cost access to platelet function testing would increase the frequency of therapeutic adjustments to ADPri treatment in routine clinical practice and (2) access to platelet function testing would improve 30-day clinical outcomes of acute MI patients treated with PCI.
Methods

Study Oversight
TRANSLATE-POPS was a multicenter, prospective, clusterrandomized trial embedded in the TRANSLATE-ACS study, a longitudinal observational study of ST-elevation MI or non-STelevation MI patients treated with PCI and ADPri therapy in the United States. 9 The study was led by the Duke Clinical Research Institute and sponsored by Daiichi Sankyo, Inc. and Eli Lilly and Company. Participating hospitals obtained institutional review board approval for participation in TRANSLATE-ACS and additional approval for participation in TRANSLATE-POPS before site randomization. All patients provided written informed consent for participation in TRANSLATE-ACS. The TRANSLATE-ACS steering committee designed and provided study oversight. Data were collected and analyzed according to a predefined protocol and statistical analysis plan.
Study Population
The design of the TRANSLATE-ACS study and its substudy, TRANSLATE-POPS, has been previously described. 9 Briefly, TRANSLATE-ACS enrolled ST-elevation MI or non-ST-elevation MI patients treated with PCI and ADPri therapy in the United States between April 8, 2010 , and October 31, 2012. Enrollment was broadly inclusive, excluding only patients who were unable or unwilling to provide written consent for longitudinal follow-up or were participating in another research study that directed the use of either an investigational or approved ADPri within the first 12 months postacute MI. TRANSLATE-ACS hospitals that were not already routinely testing platelet function (defined as testing in <30% of MI patients treated with PCI) were eligible for TRANSLATE-POPS. All patients enrolled in TRANSLATE-ACS after the date of site randomization were included in the TRANSLATE-POPS population, regardless of whether platelet function testing was performed.
Study Procedures
After institutional review board approval, each TRANSLATE-POPS site was randomly assigned access to no-cost platelet function testing (intervention arm) versus usual care. Intervention arm sites were provided an Accumetrics VerifyNow P2Y12 system and encouraged to test platelet function on all enrolled MI patients. Test results were made immediately available to the care team without any direction or algorithm as to how these results should guide treatment. Sites in the usual care arm were not provided with the VerifyNow P2Y12 system, but were permitted to perform platelet function testing as deemed clinically indicated. Other than randomization at the site level, the study remained observational, consistent with the main TRANSLATE-ACS study design. Clinicians in both arms received education via webinar regarding the prognostic significance of VerifyNow test results, as well as the results of the Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) study, which were known at that time. 6 However, treatment decisions in both arms were made by the patients' care providers without influence from the study.
The VerifyNow P2Y12 system is a US Food and Drug Administrationapproved point-of-care test that measures platelet reactivity in response to an ADP agonist using whole blood. The measurement is reported in P2Y12 reaction units (PRU). Intervention arm sites were instructed to conduct platelet function testing before discharge, at least 12 hours post-PCI, and ideally as close to discharge as possible. Testing was recommended at least 12 hours after a ≥300 mg clopidogrel loading dose or at least 2 hours after a prasugrel loading dose. In patients who did not receive a loading dose, testing was to be performed after at least 5 days of ADPri therapy, including preadmission use. Testing was to be performed in those treated with (1) eptifibatide
WHAT IS KNOWN
• The rate of high on-treatment platelet reactivity is lower with the use of higher potency adenosine diphosphate receptor inhibitors.
• Point-of-care platelet function tests can rapidly and reproducibly identify patients at increased risk of cardiovascular events who may potentially benefit from adjustments in antiplatelet therapy.
• To date, randomized studies assessing platelet function testing strategies for the purpose of treatment adjustment have not demonstrated improvement in clinical outcomes for high on-treatment platelet reactivity patients because of varying high on-treatment platelet reactivity threshold definitions, protocol-drive treatment adjustment strategies, inclusion of mostly low-risk patients, and being underpowered to examine clinical outcomes.
WHAT THE STUDY ADDS
• Using a cluster-randomized design built into an ongoing observational study, our study assessed the real-world impact of platelet function testing in a setting where clinicians were able to respond to test results without protocol-mandated treatment strategies.
• We found that access to no-cost platelet function testing had a significant but modest impact on adenosine diphosphate receptor inhibitors treatment selection and dosing in patients with acute myocardial infarction undergoing percutaneous coronary intervention and did not significantly improve patient outcomes.
or tirofiban: at least 12 hours post-discontinuation in patients with creatinine clearance (CrCl) ≥50 mL/min and at least 36 hours postdiscontinuation in patients with CrCl <50 mL/min; (2) abciximab: a minimum of 48 hours, but ideally 14 days, post-discontinuation; and (3) bivalirudin: at least 3 hours post-discontinuation in patients with CrCl ≥30 mL/min and at least 6 hours post-discontinuation in patients with CrCl <30 mL/min.
Study End Points
The primary end point was the frequency of ADPri therapy adjustment during the index MI hospitalization. Therapeutic adjustments included dose changes (increasing or lowering) or switching (clopidogrel to prasugrel/ticagrelor or vice versa). Secondary end points included the incidence of major adverse cardiac events (MACE; defined as composite of all-cause death, MI, stroke, or unplanned coronary revascularization) and bleeding events (defined using the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO] criteria) at 30 days post-PCI. 10 End points were validated independently by study physicians based on medical record review, as previously described. 9 The Bleeding Academic Research Consortium (BARC) bleeding definition was introduced in 2011 and added to the study as a secondary bleeding definition. 11 Further secondary analyses compared MACE and bleeding risks at 1 year post-PCI.
Statistical Analysis
Differences in baseline characteristics between randomized groups were compared using random effects models with random intercepts for site. Continuous variables were assessed using linear mixed models, binary variables were assessed using logistic mixed models, and variables with >2 categories were assessed using multinomial mixed models.
All end points were primarily analyzed using intention-to-treat analyses. Among patients initially treated with clopidogrel or prasugrel, we performed a logistic regression model with random effects to compare the frequency of therapeutic adjustment in the intervention arm versus the usual care arm. The model included an indicator variable for intervention arm and the following covariates: age, sex, race, ethnicity, insurance status, prior MI, prior stroke/transient ischemic attack, diabetes mellitus, ST-elevation MI (versus non-ST-elevation MI) presentation, multivessel disease, drug-eluting stent implantation, and geographic region. The primary analysis was summarized using the odds ratio (OR) and 95% confidence interval (CI) from the logistic regression model with random effects. For the 30-day MACE and bleeding event analyses, logistic regression with random intercepts was applied to assess differences between the intervention and usual care arms. For 1-year MACE and bleeding event analyses, Cox regression with random intercepts to account for hospital clustering was performed. Patients were censored at the time of discontinuation from the study. A secondary as-treated analysis compared intervention arm patients who received platelet function testing with usual care arm patients without platelet function testing. Multivariable logistic regression was performed for 30-day MACE and bleeding events and Cox regression for 1-year MACE and bleeding events, with adjustments for potential biases (list of covariates in Supplement I in the Data Supplement).
We calculated that randomization of 150 sites would be required to provide >90% power with a 2-sided Type I error rate of 0.05 based on 10% lost-to-follow-up and the following assumptions: (1) overall, there would be a 3:1 ratio of initial clopidogrel to prasugrel treatment, and the rate of HPR (PRU ≥235) with clopidogrel would be 30%; (2) in the intervention arm, two-thirds of clopidogrel-treated patients with HPR would have therapeutic adjustments, whereas 10% of clopidogrel-treated patients without HPR and 10% of prasugrel-treated patients would have their therapy adjusted; and (3) in the usual care arm, 10% of all clopidogrel-treated patients and 20% of the prasugrel-treated patients would have therapy adjustment. On October 31, 2012, enrollment in the parent TRANSLATE-ACS study ended; therefore, TRANSLATE-POPS enrollment was also discontinued.
Results
Study Population
From May 18, 2011, to October 31, 2012, a total of 100 sites were randomized: 50 sites were randomly assigned to receive the VerifyNow P2Y12 device and no-cost platelet function testing (intervention arm) and 50 sites to usual care. The baseline characteristics between the 1987 patients in the intervention arm and the 1830 patients at usual care sites are presented in Table 1 . No significant differences were observed between the groups, except for a higher proportion of female patients in the intervention arm. Rates of aspirin and ADPri use before MI admission, as well as angiographic characteristics, were well-balanced between groups.
Prasugrel was the first ADPri administered to 24.5% of intervention arm and 27.2% of usual care patients (P=0.18). Initial doses are shown in Table 2 . We observed modestly higher rates of multivessel PCI and drug-eluting stent use among patients treated in the intervention arm, although these differences were not statistically significant when compared with the usual care arm.
Study Intervention
Among intervention arm sites, the test was performed in 1319 of 1987 (66.4%) patients; 48 (2.4%) patients had blood drawn but no test results (error message on VerifyNow device). Of those not tested at intervention sites, 591 patients or their treating clinicians declined testing, 77 did not have blood drawn for testing. In contrast, only 23 of 1830 (1.3%) patients underwent VerifyNow platelet function testing in the usual care arm.
The median time to platelet function testing was 39 hours post-PCI (interquartile range from 23 to 51 hours) in the intervention arm and 26 hours (interquartile range 18-45 hours) in the usual care arm. Among tested intervention arm patients, 245 of 1271 (19.3%) had a PRU value ≥235 and 338 of 1271 (26.6%) had a PRU value ≥208. Among tested patients initially started on clopidogrel, 238 of 965 (24.7%) had a PRU ≥235 and 327 of 965 (33.9%) had a PRU ≥208. Among patients initially started on prasugrel, 8 of 307 (2.6%) had a PRU ≥235 and 12 of 307 (3.9%) had a PRU ≥208. Among the 23 usual care arm patients who received platelet function testing, 6 (26.1%) had PRU values ≥208 and ≥235; 5 of these 6 patients were initially treated with clopidogrel.
Primary End Point
The incidence of ADPri therapy adjustment during the index hospitalization was higher among intervention arm patients than usual care arm patients (14.8% versus 10.5%, P=0.0042, OR 1.68 [95% CI 1.18-2.40]) after accounting for clustering of responses within a site. Most of the change was a switch to another ADPri during the index hospitalization (Table 3) . Patients started on clopidogrel were more likely to be switched to prasugrel or ticagrelor in the intervention arm than in the usual care arm (13.7% versus 8.7%, P=0.002). Rates of switch to clopidogrel were similar between groups. Dose changes in ADPri therapy were infrequent during the index hospitalization and not significantly different between groups (1.6% versus 1.1%, P=0.14). Dose increases were observed in 10/28 TRANSLATE-POPS Study (35.7%) patients in the intervention arm and 3/18 (16.7%) patients in the usual care arm. Among tested patients in the intervention arm, 32.2% of patients with a PRU value ≥235 had an adjustment in ADPri therapy compared with 12.8% with PRU values <235 (P<0.001); 29.9% versus 11.9% using a PRU threshold of 208 (P<0.001). Rates of therapy adjustment within the next 6 weeks after discharge were low and not significantly different between intervention and usual care arm patients (Table 3) .
Secondary End Points
Between the 2 groups, there were no significant differences in the incidence of MACE by 30 days after PCI (Figure 1 ; OR 0.94, 95% CI 0.66, 1.34) or any of its individual components ( Table 4 ). The incidence of any GUSTO-defined bleeding was also not significantly different between groups (OR 0.86, 95% CI 0.55, 1.34; Figure 2 ). Differences in BARC-defined bleeding are shown in Table 4 ; there was no significant difference in the risk of any BARC bleeding at 6 weeks (OR 1.18, 95% CI 0.93, 1.50). No differences were seen in the severity of bleeding or the incidence of bleeding events stratified by initial ADPri use (Table 4) .
Secondary Analyses
To study the as-treated[AQ: Per style, quotes should not be used for emphasis. Hence, they have been deleted throughout the article. Please confirm whether the change made throughout is appropriate.] effect, we also compared the 1319 patients in the intervention arm who received platelet function testing with the 1807 patients in the usual care arm who did not undergo testing. The incidence of ADPri therapy adjustment during the index hospitalization was higher among intervention arm patients than usual care arm patients (16.4% versus 10.2%, P<0.0001, OR 2.15, 95% CI 1.48, 3.13), yet the incidence of MACE and bleeding events by 30 days after PCI still did not significantly differ between groups (OR 0.73, 95% CI 0.49, 1.10 and OR 0.84, 95% CI 0.50, 1.41, respectively). 
Discussion
This study is unique in embedding a cluster-randomized trial design within an observational framework to study the impact of no-cost platelet function testing on routine community practice. Major findings include (1) a significant proportion of acute MI patients treated with ADPri therapy had HPR when tested; (2) access to no-cost platelet function testing had a significant but modest impact on ADPri therapy choice and dosing; but (3) had no significant impact on 30-day or 1-year outcomes when compared with usual care.
The routine use of platelet function testing remains controversial. Platelet function testing identifies patients with an inadequate platelet inhibition response to treatment 12, 13 who are at higher risk of MACE. 2, 14 The association of HPR with downstream MACE is stronger in ACS patients than those with stable coronary artery disease. 15, 16 Current practice guidelines provide a IIb recommendation for platelet function testing if the result may alter management or if the patient is at high risk of poor clinical outcomes. 4, [17] [18] [19] [20] Yet previous studies have demonstrated conflicting results with regard to systematic platelet function testing strategies for the purpose of treatment adjustment. Small studies have shown that intensifying platelet inhibition reduces the rates of MI and stent thrombosis in high-risk patients. 21, 22 Nevertheless, the GRAVITAS trial demonstrated no advantage to clopidogrel dose doubling among PCI patients with PRU values ≥230. 6 Most large randomized studies have been performed in predominantly lower risk, stable PCI populations and either showed no clinical improvement with test-guided therapy adjustment 8 or were terminated early because of low event rates. 7 One nonrandomized study of ACS patients showed similar event rates between patients who had normalization of platelet aggregation test results with antiplatelet treatment adjustment and those with persistently abnormal results. 23 In light of these conflicting results, there remains considerable controversy over whether platelet function testing should be performed, the appropriate threshold to trigger change in therapy, and the most effective response to HPR.
TRANSLATE-POPS differs from previous trials in several important ways: (1) building cluster randomization into an observational registry created a natural experiment assessing how platelet function testing would be used in community practice and whether patient outcomes would be improved if it was made routinely available without concerns about reimbursement or appropriateness of testing; (2) allowing clinicians to decide how to integrate platelet function testing results into their practice by choosing a PRU threshold that would trigger therapy adjustment for an individual patient (which was pertinent because clinical trials during this time period used varying PRU thresholds) 6, 7 ; and (3) allowing clinicians to select a treatment strategy, whether it was changing the drug, changing the dose, or the choice not to respond to platelet function test results. The fact that TRANSLATE-POPS clinicians did not have to adhere to the protocol-driven treatment decisions demonstrates the pragmatic nature of this trial and, consequently, is more reflective of real-world clinical decisions based on an individual patient's needs and capabilities (eg, affordability and adherence).
We observed low rates of platelet function testing during usual care, but two-thirds of patients received testing in the intervention arm. Access to no-cost platelet function testing had a significant but modest impact on antiplatelet therapy choice and dosing. Several reasons may explain these findings: First, despite the prothrombotic milieu of an acute MI, the rate of HPR was lower than observed in previous studies. 8, 16, 24, 25 This may be partially attributed to greater upfront use of prasugrel compared with previous studies, although HPR has also been observed in ACS patients treated with prasugrel. 5 The delay of platelet function testing as long as possible after antiplatelet initiation may also result in lower rates of HPR because assessments before achieving steady state might overestimate the proportion of poor-responders. 26 Second, therapeutic changes in response to testing may have occurred after the index hospitalization; however, we found low rates of therapeutic adjustment in the first 6 weeks postdischarge. Third, given the conflicting evidence supporting testingguided antiplatelet treatment, clinicians may be uncertain how to respond to test results. Fourth, although platelet function is a modifiable marker of risk, its modification may not †Denominator includes all patients discharged on ADP receptor information with medication information at 6 weeks. TRANSLATE-POPS Study necessarily influence prognosis. 27 A significant determinant of on-treatment reactivity is pretreatment reactivity, which can be as a result of nonmodifiable clinical and anatomic characteristics. 28 Furthermore, consistent with other studies, we observed switching in both groups that appeared to be independent of platelet function test results. 29 Finally, despite evidence of cardiovascular benefit with intensified antiplatelet treatment, 30, 31 current US practice still strongly favors clopidogrel as shown in our study. This preference, further fueled by the availability and cost of generic clopidogrel, may prevent clinicians from changing therapy even with demonstrated HPR.
We did not observe a significant impact of no-cost platelet function testing on ischemic and bleeding outcomes. Because not all patients treated at intervention arm sites underwent Comparison of MACE. Comparison of MACE between patients treated in the device and usual care groups. CI indicates confidence interval; MACE, major adverse cardiac event; OR, odds ratio; and PCI, percutaneous coronary intervention. TRANSLATE-POPS Study testing, we conducted a secondary as-treated analysis comparing intervention arm patients who underwent testing to patients without testing in the usual care arm. This comparison again showed modestly higher rates of therapy adjustment associated with platelet function testing, but no significant differences in MACE or bleeding outcomes between groups. Given the small magnitude of change in treatment, we were unlikely to detect significant outcome differences in this study. Importantly, in phase III clinical trials, routine use of higher potency ADPris have improved outcomes when compared with clopidogrel and, per the European guidelines, have become the standard of care for patients with ACS undergoing PCI. 19 The value of platelet function testing to guide the choice of ADPri's, as compared with the unrestricted use of these higher potency ADPris, remains to be established.
We acknowledge some limitations related to the design and conduct of the study. First, platelet function testing was performed using only one method of testing and at a single time point during the index hospitalization; therefore, we have no information on whether antiplatelet therapy adjustment reduced the rate of HPR. Second, because most of the therapeutic adjustments appeared not to be driven by platelet function testing results, we cannot compare outcomes between patients who had therapy change in response to testing versus those who did not. Third, TRANSLATE-POPS resulted in only 100 of 150 planned sites randomized because of the termination of enrollment in the parent TRANSLATE-ACS study. Adequate powering of a cluster-randomized study depends on several factors, including number of sites randomized, number of patients enrolled per site, degree of intracluster correlation, assumed adherence rates in intervention and control groups, and predicted response to the intervention. In our study, given the lower than expected penetrance of platelet function testing in the intervention arm (66%) and low rates of observed therapeutic adjustment, we were underpowered to detect significant differences in MACE or bleeding end points. Pragmatic study designs are needed for future trials to detect small but potentially meaningful differences in outcomes between strategies.
In conclusion, TRANSLATE-POPS was a cluster randomized trial designed to assess the real-world impact of platelet function testing. The study demonstrated that access to no-cost platelet function testing had a significant but modest impact on ADPri treatment selection and dosing in patients with an acute MI undergoing PCI. Because the magnitude of change in treatment was small, access to no-cost platelet function testing did not significantly improve post-MI patient outcomes.
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